These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31980117)

  • 1. Role of Glucagon in Automated Insulin Delivery.
    Wilson LM; Jacobs PG; Castle JR
    Endocrinol Metab Clin North Am; 2020 Mar; 49(1):179-202. PubMed ID: 31980117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
    Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
    J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Dual-Hormone Closed-Loop Delivery System in the Future.
    Bally L; Thabit H; Hovorka R
    Diabetes Technol Ther; 2016 Aug; 18(8):452-4. PubMed ID: 27500812
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.
    Abitbol A; Rabasa-Lhoret R; Messier V; Legault L; Smaoui M; Cohen N; Haidar A
    Diabetes Technol Ther; 2018 Mar; 20(3):189-196. PubMed ID: 29393675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
    Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
    Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated Insulin Delivery-The Light at the End of the Tunnel.
    Turksoy K; Frantz N; Quinn L; Dumin M; Kilkus J; Hibner B; Cinar A; Littlejohn E
    J Pediatr; 2017 Jul; 186():17-28.e9. PubMed ID: 28396030
    [No Abstract]   [Full Text] [Related]  

  • 11. Current Management of Glycemia in Children with Type 1 Diabetes Mellitus.
    Sperling MA; Laffel LM
    N Engl J Med; 2022 Mar; 386(12):1155-1164. PubMed ID: 35320645
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetes: Artificial pancreas--first head-to-head comparison of dual-hormone and single-hormone systems.
    Holmes D
    Nat Rev Endocrinol; 2015 Feb; 11(2):63. PubMed ID: 25511314
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon.
    Jacobs PG; El Youssef J; Castle JR; Engle JM; Branigan DL; Johnson P; Massoud R; Kamath A; Ward WK
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():397-400. PubMed ID: 22254332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study.
    Sherwood JS; Jafri RZ; Balliro CA; Zheng H; El-Khatib FH; Damiano ER; Russell SJ; Putman MS
    J Cyst Fibros; 2020 Jan; 19(1):159-161. PubMed ID: 31420176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Model Predictive Control of Bihormonal Artificial Pancreas System Based on Switching Control and Dynamic R-parameter.
    Tang F; Wang Y
    J Diabetes Sci Technol; 2017 Nov; 11(6):1112-1123. PubMed ID: 28728434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of a dual-hormone model predictive control for artificial pancreas with exercise model.
    Resalat N; El Youssef J; Reddy R; Jacobs PG
    Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2270-2273. PubMed ID: 28324962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.
    Taleb N; Haidar A; Messier V; Gingras V; Legault L; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 Jan; 19(1):13-23. PubMed ID: 27629286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A coordinated control strategy for insulin and glucagon delivery in type 1 diabetes.
    Herrero P; Bondia J; Oliver N; Georgiou P
    Comput Methods Biomech Biomed Engin; 2017 Oct; 20(13):1474-1482. PubMed ID: 28929796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
    Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
    Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
    Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
    Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.